MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Eli Lilly and Co.

Avatud

SektorTervishoid

866.17 1.96

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

845.8

Max

871.37

Põhinäitajad

By Trading Economics

Sissetulek

7.8B

8.8B

Müük

2.1B

14B

P/E

Sektori keskmine

70.036

57.333

Aktsiakasum

5.32

Dividenditootlus

0.71

Kasumimarginaal

65.172

Töötajad

47,000

EBITDA

1.2B

6.1B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+16.73% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.71%

2.63%

Järgmine tulemuste avaldamine

1. mai 2025

Järgmine aktsia dividendi kuupäev (ex-date)

14. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-50B

735B

Eelmine avamishind

864.21

Eelmine sulgemishind

866.17

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

Eli Lilly and Co. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. apr 2025, 09:26 UTC

Suurimad hinnamuutused turgudel

Novo Nordisk Shares Fall After Data From New Eli Lilly Pill

18. apr 2025, 15:57 UTC

Suurimad hinnamuutused turgudel

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

17. apr 2025, 11:52 UTC

Suurimad hinnamuutused turgudel

Eli Lilly Shares Jump Premarket After First Pill for Diabetes, Weight Loss Shows Positive Study Results

9. apr 2025, 18:18 UTC

Suurimad hinnamuutused turgudel

Pharma Shares Reverse Losses After Tariff Pause

9. apr 2025, 09:39 UTC

Suurimad hinnamuutused turgudel

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

4. apr 2025, 22:38 UTC

Kuumad aktsiad

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1. apr 2025, 23:15 UTC

Suurimad hinnamuutused turgudel

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

22. apr 2025, 09:31 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: Tesla, Novo Nordisk, Hertz -- WSJ

17. apr 2025, 18:27 UTC

Peamised uudised

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- Update

17. apr 2025, 10:45 UTC

Peamised uudised

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- WSJ

11. apr 2025, 16:23 UTC

Omandamised, ülevõtmised, äriostud

Novo Remade Denmark. Then Came the Stock Selloff. -2-

11. apr 2025, 16:23 UTC

Omandamised, ülevõtmised, äriostud

Novo Remade Denmark. Then Came the Stock Selloff. -- Barrons.com

11. apr 2025, 09:30 UTC

Peamised uudised

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

11. apr 2025, 05:00 UTC

Peamised uudised

Wall Street Pulls Back on the Weight-Loss Drug Hype -- Barrons.com

10. apr 2025, 05:00 UTC

Tulu

Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the Next Winner. -- Barrons.com

8. apr 2025, 21:26 UTC

Tulu

Pfizer Stock's Fall to '97 Level Lifts Yield Near 8%. Dividend Looks Safe. -- Barrons.com

2. apr 2025, 16:53 UTC

Peamised uudised

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

1. apr 2025, 22:31 UTC

Peamised uudised

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1. apr 2025, 21:47 UTC

Peamised uudised

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

19. märts 2025, 15:54 UTC

Peamised uudised

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

14. märts 2025, 09:30 UTC

Peamised uudised

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

28. veebr 2025, 12:00 UTC

Peamised uudised

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26. veebr 2025, 15:14 UTC

Peamised uudised

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- Update

26. veebr 2025, 14:30 UTC

Peamised uudised

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- WSJ

10. veebr 2025, 12:00 UTC

Peamised uudised

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7. veebr 2025, 10:30 UTC

Peamised uudised

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6. veebr 2025, 16:16 UTC

Peamised uudised
Tulu

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6. veebr 2025, 14:56 UTC

Tulu

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

6. veebr 2025, 14:32 UTC

Market Talk
Tulu

Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk

6. veebr 2025, 13:18 UTC

Peamised uudised
Tulu

Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

Võrdlus sarnastega

Hinnamuutus

Eli Lilly and Co. Prognoos

Hinnasiht

By TipRanks

16.73% tõus

12 kuu keskmine prognoos

Keskmine 1,003.6 USD  16.73%

Kõrge 1,124 USD

Madal 888 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Eli Lilly and Co. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

19 ratings

19

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

732.41 / N/AToetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.